Gene-IT’s GenomeQuest(TM) Achieves GeneChip-compatible(TM) Status with Affymetrix GeneChip(R) Microarray Platform
Gene-IT today announced that its GenomeQuest(TM) has achieved GeneChip-compatible(TM) status with the Affymetrix Inc. (Nasdaq: AFFX) GeneChip(R) microarray platform, and that it has joined the Affymetrix GeneChip-compatible(TM) Applications Program, which provides customers with a broad spectrum of software solutions for biomedical research and development. As a GeneChip-compatible(TM) software provider, Gene-IT is committed to seamlessly integrating its GenomeQuest(TM) with the Affymetrix GeneChip platform.
Integration of Affymetrix GeneChip microarray annotations into GenomeQuest provides biologists with timely and comprehensive microarray annotation reports. GenomeQuest integrates lists of identifiers with sequence comparison for inter- and cross-species searching of up-to-date biological and patent reference data. Search results are automatically formatted into reports, which can be published as Microsoft Word documents. Results can also be uploaded to popular microarray analysis packages. GenomeQuest also maintains continuous surveillance of all of its data sources, and automatically sends email alerts when new information is discovered. Sequence identifiers or full-length RNA transcripts can be easily extracted for further experimentation, such as PCR.
“For the first time, customers have a single, commercially-supported searching and data integration solution that combines public, private, patent, and now Affymetrix GeneChip microarray data. Our service continuously updates this information on in-house computing resources without the need for human intervention,” states Ron Ranauro, CEO of Gene-IT.
“Affymetrix is dedicated to providing our customers with effective and innovative solutions for applying microarray data in biomedical research and development,” said Steve Lincoln, Vice President of Informatics at Affymetrix. “We are pleased to be working with Gene-IT to expand our mutual customers’ knowledge of the genes and variants which can be studied using our GeneChip microarrays.”
About Gene-IT
Gene-IT combines large-scale sequence comparison and mining software with managed services so that bench scientists, investigators, lawyers, and non-specialist users can benefit from up-to-date information available in public, private, and patent sequence databases.
Gene-IT’s innovative sequence-centric technology overcomes the limits of relational-based systems by allowing sequence annotation data to “travel” with the sequence into all results – whether from sequence comparison or sequence look-ups – to allow efficient screening of results, enabling faster decision-making and improved R&D efficiency.
Gene-IT is headquartered in North America near Boston, Massachusetts and in Europe near Paris, France. For more information, please contact Susan Barry at 508-754-7300, or visit Gene-IT on the web at: www.genomequest.com .
About the Affymetrix Developers Network
Through one of the largest third-party software developer communities within the life science industry, Affymetrix works with ADN participants to provide a broad spectrum of solutions for leveraging gene expression and genetic variation analysis in both biomedical research and development. Membership in ADN is free of charge for both commercial and academic software developers. For more information on the ADN Program please visit www.affymetrix.com/genechip/developer . Visit the GeneChip-compatible Software Solutions Catalog at www.affymetrix.com/genechip/compatible .
About Affymetrix
Affymetrix scientists invented the world’s first microarray in 1989 and began selling the first commercial microarray in 1994. Since then, Affymetrix GeneChip(R) technology has become the industry standard in molecular biology research. Affymetrix GeneChip technology is used by the world’s top pharmaceutical, diagnostic and biotechnology companies as well as leading academic, government and not-for-profit research institutes. More than 1,200 systems have been shipped around the world and more than 3,000 peer-reviewed papers have been published using the technology. Affymetrix’ patented photolithographic manufacturing process provides the most information capacity available today on a microarray, enabling researchers to use a whole-genome approach to analyze the relationship between genetics and health. Headquartered in Santa Clara, Calif., Affymetrix has subsidiaries in Europe and Asia in addition to manufacturing facilities in Sacramento, Calif. and Bedford, Mass. The company has about 900 employees worldwide. For more information about Affymetrix, please visit the company’s website at www.Affymetrix.com .
